Generating Evidence that RABEP2 is a Novel GSK3 Substrate that Represents a Single Therapeutic Target to Reduce Both Hyperglycemia and Microvascular Disease in Diabetes (joint with Glasgow Uni)

Project Details

StatusActive
Effective start/end date1/06/2031/05/23

Funding

  • British Heart Foundation (PG/19/79/34742): £281,116.00